Mylan (MYL) Surges on DOJ EpiPen Medicaid Rebate Settlement

October 7, 2016 5:01 PM EDT

Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.

Mylan (NASDAQ: MYL) is trading up 9% after-hours Friday after the company it agreed to the terms of a $465 million settlement with the DOJ and other government agencies that will resolve questions that have been raised about the classification of EpiPen for purposes of the Medicaid Drug Rebate Program.

The company's 2016 guidance was also cut, but very little.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Momentum Movers, Trader Talk

Add Your Comment